Alembic Ltd (ALEMBICLTD) is currently trading at 90.90 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Alembic Limited is a veteran manufacturer of bulk drugs and pharmaceuticals for human and animal healthcare in India. Founded in 1907, it has developed strong expertise in APIs and formulations, with significant production facilities in Vadodara and Solan. Alembic's history of pharmaceutical innovation includes significant developments such as the launch of Erythromycin under Althrocin in 1972, which became a bestseller in India by 1997. The company has diversified its business to include real estate and power generation sectors, leveraging its captive power plant operations and launching notable real estate projects like Samsara and VEDA. Alembic's strategic ventures include the expansion of its API capacities and acquiring significant pharmaceutical and API facilities, boosting its operational capabilities over the years.

Over the past 52 weeks, Alembic Ltd has traded between a low of ₹70.64 and a high of ₹108.55. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Alembic Ltd has a market capitalization of approximately 2,352.38. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Alembic Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 7.34 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 2,352.38 Cr, Alembic Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Alembic Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Alembic Ltd is 7.34. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Revenue from operations rose 17% YoY to ₹1,770 crore, while net profit was reported at ₹157 crore, down about 12% YoY.

Revenue from operations rose 17% YoY to ₹1,770 crore, while net profit for the quarter was reported at ₹157 crore (also cited around ₹156 crore in one disclosure).

Alembic said it received USFDA approval for its generic Lamotrigine tablets used to treat seizures, with an ANDA therapeutically equivalent to GlaxoSmithKline’s Lamictal.

Dapagliflozin is a medication used to treat type 2 diabetes and reduce the risk of heart failure. The final USFDA approval is significant for Alembic as it allows the company to launch a generic version in the U.S. market, which is estimated to be worth over $10 billion, and includes a 180-day shared exclusivity period.